Chemed Corporation — 2013 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2013, not Q4 alone. Chemed operates two segments: VITAS, a hospice and palliative-care provider, and Roto-Rooter, a plumbing and drain-cleaning services business. The full financial statements and MD&A are incorporated by reference from the 2013 Annual Report to Stockholders and are not included in the supplied filing text.
Financial performance and position
- Revenue, profit, cash flow, margins and liquidity: The supplied text does not provide clear consolidated values or year-over-year results. It refers readers to the incorporated annual report.
- Debt: Long-term debt had a carrying value of $183.6 million and estimated market value of $193.0 million at year-end. Chemed reported no variable-rate debt outstanding at December 31, 2013. It disclosed 1.875% convertible senior notes due May 2014, which could dilute shareholders depending on the stock price. The text does not state cash, current liquidity, or available borrowing capacity.
- VITAS payer exposure: More than 90% of VITAS net patient service revenue came from Medicare and Medicaid, making reimbursement rates, eligibility rules and claims reviews material financial drivers. A 2% federal Medicare reimbursement cut took effect April 1, 2013.
- Capital returns: Chemed paid quarterly dividends of $0.18, $0.18, $0.20 and $0.20 per share in 2013. The share-repurchase table reports approximately 1.36 million shares repurchased during the year. The board authorized another $100 million under the repurchase program on February 21, 2014.
Material changes and unusual items
- Roto-Rooter recorded $14.8 million of 2013 operating expense for a labor-law settlement of $14.3 million plus payroll taxes; the disclosed after-tax settlement cost was $9.0 million. The amount was accrued at year-end.
- VITAS recorded $10.5 million of 2013 operating expense for a settlement of $10.3 million plus payroll taxes; the disclosed after-tax cost was $6.5 million. The settlement was paid in 2013.
- Chemed recorded a $6.0 million securities-litigation settlement, funded by its insurer, as an accrual and offsetting prepaid asset. Court approval remained pending at the report date.
- Net costs to comply with government investigations of VITAS were $2.1 million in 2013, compared with $1.2 million in each of 2012 and 2011; the filing also notes a one-time $1.0 million insurance reimbursement for certain legal costs.
Outlook, risks and contingencies
- The filing provides no specific financial guidance. Management emphasizes VITAS’s dependence on government reimbursement and its ability to manage labor and other care-delivery costs. Rate limits or cuts, audits, denials and recoupments could pressure revenue and profitability.
- Chemed and VITAS faced consolidated federal False Claims Act litigation and related investigations alleging improper Medicare hospice billing, including claims involving patient eligibility and continuous home care. The government sought treble damages and statutory penalties; the defendants stated they would defend the matters vigorously. Outcomes and potential exposure were not clearly quantified in the supplied text.
- At year-end, Chemed accrued $1.7 million for environmental cleanup and related costs associated with the former DuBois business. It also disclosed contingent exposure of up to $14.9 million beyond the accrual, which management did not consider probable enough to record.
- Other risks include hospice staffing shortages and wage inflation, referral-source competition, licensing and certificate-of-need requirements, Roto-Rooter competition and weather sensitivity, cyber incidents, and potential hurricane disruption to VITAS operations in south Florida.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the fourth quarter.
Important facts for investors to verify
- Consult the incorporated 2013 Annual Report for revenue, earnings, cash flow, segment results, margins, cash balances, and full year-over-year comparisons; those values are not clear in the supplied text.
- Review the terms, repayment or conversion outcome of the May 2014 convertible notes, and the related dilution and refinancing implications.
- Track the consolidated VITAS government billing litigation and investigations, including potential damages, any settlement or recoupment, and continuing legal costs.
- Assess Medicare and Medicaid reimbursement changes, hospice cap exposure, and whether staffing-cost inflation outpaces rate adjustments.
- Confirm the status and ultimate cost of the DuBois environmental matters and the approval and funding of the securities-litigation settlement.